Oncology Corporate Profile
AstraZeneca PLC discovers, develops, manufactures, and markets prescription pharmaceuticals, biologics, and vaccines in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide.
|Arimidex®||anastrozole||Treatment of advanced breast cancer in postmenopausal women. `Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.|
|Caprelsa®||vandetanib||Caprelsa® is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use of Caprelsa® in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of Caprelsa®.|
|Casodex® 150 mg||bicalutamide||Patients with locally advanced prostate cancer as immediate therapy either alone or as adjuvant to treatment of curative intent. Patients with non-metastatic prostate cancer for whom immediate hormonal therapy is indicated. Patients with metastatic prostate cancer for whom surgical or medical castration is not indicated or not acceptable.|
|Casodex® 50 mg||bicalutamide||Advanced prostate cancer in combination with LHRH analogue therapy or surgical castration.|
|Faslodex®||fulvestrant||Faslodex® is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy; treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.|
|Imfinzi™||durvalumab||Imfinzi™ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with:|
- Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
|Iressa®||gefitinib||Treatment of patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have previously received chemotherapy or who are not suitable for chemotherapy.|
|Lynparza®||olaparib||Lynparza® is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.|
Nolvadex® is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, Nolvadex® is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from Nolvadex® therapy.
Adjuvant Treatment of Breast Cancer
Nolvadex® is indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some Nolvadex® adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Nolvadex® is indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant Nolvadex® therapy is likely to be beneficial. Nolvadex® reduces the occurrence of contralateral breast cancer in patients receiving adjuvant Nolvadex® therapy for breast cancer.
Ductal Carcinoma in Situ (DCIS)
In women with DCIS, following breast surgery and radiation, Nolvadex® is indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with Nolvadex® for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of Nolvadex® therapy. Current data from clinical trials support five years of adjuvant Nolvadex® therapy for patients with breast cancer.
Reduction in Breast Cancer Incidence in High Risk Women
Nolvadex® is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label).
NOLVADEX is indicated only for high-risk women. 'High risk is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer of 1.67%, as calculated by the Gail Model.
Examples of combinations of factors predicting a 5-year risk of 1.67% are:
Age 35 or older and any of the following combination of factors:
* One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or
* At least 2 first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or
Age 40 or older and any of the following combination of factors:
* One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or
* At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or
* One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia.
Age 45 or older and any of the following combination of factors:
* At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or
* One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more.
Age 50 or older and any of the following combination of factors:
* At least 2 first degree relatives with a history of breast cancer; or
* History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or
* History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more.
Age 55 or older and any of the following combination of factors:
* One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or
* History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older.
Age 60 or older and:
* 5-year predicted risk of breast cancer of 1.67%, as calculated by the Gail Model.
For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-800-544-2007.
There are insufficient data available regarding the effect of NOLVADEX on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of NOLVADEX in these patients.
After an assessment of the risk of developing breast cancer, the decision regarding therapy with NOLVADEX for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial, NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk.
|Tagrisso®||osimertinib||Tagrisso® is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.|
|Tagrisso®||osimertinib||Tagrisso® is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy|
|Zoladex®||goserelin||Prostate cancer suitable for hormonal manipulation. Breast cancer in pre and perimenopausal women suitable for hormonal manipulation. Endometriosis. Uterine Fibroids. Endometrial thinning. Assisted Reproduction.|
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|durvalumab (+ tremelimumab)||PD-L1 mAb + CTLA-4 mAb||1st line Bladder cancer||III|
|acalabrutinib||BTK inhibitor||1st line Chronic Lymphocytic Leukemia (CLL)||III|
|durvalumab (+ tremelimumab)||PD-L1 mAb + CTLA-4 mAb||1st line Non Small Cell Lung Cancer (NSCLC)||III|
|durvalumab (+ tremelimumab)||PD-L1 mAb + CTLA-4 mAb||1st line squamous cell carcinoma of the Head & Neck||III|
|durvalumab (+ tremelimumab)||PD-L1 mAb + CTLA-4 mAb||2nd line squamous cell carcinoma of the Head & Neck||III|
|durvalumab||PD-L1 mAb||Bladder cancer||III|
|moxetumomab pasudotox||anti-CD22 recombinant immunotoxin||Hairy cell Leukemia||III|
|durvalumab (+ epacadostat)||PD-L1 mab (+ CTLA-4 mAb or STAT3 inhibitor)||ocally-advanced unresectable Non Small Cell Lung Cancer (NSCLC)||III||Incyte|
|savolitinib||MET tyrosine kinase inhibitor||Papillary Renal cell carcinoma (RCC)||III|
|selumetinib||MEK inhibitor||Thyroid cancer||III|
|Tagrisso / osimertinib||EGFR tyrosine kinase inhibitor||1st line Non Small Cell Lung Cancer (NSCLC)||III|
|Tagrisso / osimertinib / AZD9291||EGFR tyrosine kinase inhibitor||2nd line Non Small Cell Lung Cancer (NSCLC)||III|
|Tagrisso / osimertinib / AZD9291||EGFR tyrosine kinase inhibitor||Non Small Cell Lung Cancer (NSCLC)||III|
|AZD5363||AKT kinase inhibitor||Breast cancer||II|
|Lynparza (+ AZD6738)||PARP inhibitor + ATR inhibitor||Gastric cancer||II|
|durvalumab + tremelimumab®||PD-L1 mAb + CTLA-4 mAb||Gastric cancer||II|
|durvalumab + tremelimumab®||PD-L1 mAb + CTLA-4 mAb||Hepatocellular carcinoma (HCC)||II|
|MEDI-573||IGF mAb||Metastatic Breast cancer||II|
|AZD1775 (+ chemotherapy)||Wee1 inhibitor||Ovarian cancer||II|
|savolitinib (+ volitinib)||MET tyrosine kinase inhibitor||Papillary Renal cell carcinoma (RCC)||II|
|AZD4547||FGFR tyrosine kinase inhibitor||Various cancer types||II|
|AZD1775||Wee1 inhibitor||Various cancer types||II|
|durvalumab (+ MEDI0680)®||PD-L1 mAb + PD-1 mAb||Various cancer types||II|
|durvalumab||PD-L1 mAb||Various cancer types||II|
|vistusertib||mTOR serine/threonine kinase inhibitor||Various cancer types||II|
|Tagrisso / osimertinib (+ durvalumab or selumetinib or savolitinib) / AZD9291||EGFR tyrosine kinase inhibitor (+ PD-L1 mAb or MEK inhibitor or MET tyrosine kinase inhibitor)||Non Small Cell Lung Cancer (NSCLC)||II|
|AZD9496||selective oestrogen receptor downregulator (SERD)||Breast cancer||I|
|durvalumab (+ tremelimumab or AZD9150)||PD-L1 mab (+ CTLA-4 mAb or STAT3 inhibitor)||Diffuse Large B-Cell Lymphoma (DLBCL)||I|
|durvalumab (+ dabrafenib and trametinib)||PD-L1 mAb+ BRAF inhibitor + MEK inhibitor||Melanoma||I|
|durvalumab (+ Iressa)||PD-L1 mAb+ EGFR tyrosine kinase inhibitor||Non Small Cell Lung Cancer (NSCLC)||I|
|AZD0156||ATM serine/threonine kinase inhibitor||Various cancer types||I|
|AZD4635||A2aR inhibitor||Various cancer types||I|
|AZD281||ATM serine/threonine kinase inhibitor||Various cancer types||I|
|AZD6738||ATR serine/threonine kinase inhibitor||Various cancer types||I|
|AZD9150||STAT3 inhibitor||Various cancer types||I|
|AZD8186||PI3 kinase beta inhibitor||Various cancer types||I|
|MEDI4276||HER2 bispecific ADC mAb||Various cancer types||I|
|MEDI1873||GITR agonist fusion protein||Various cancer types||I|
|MEDI0680||PD-1 mAb||Various cancer types||I|
|MEDI0562||Humanized OX40 agonist||Various cancer types||I|
|MEDI-565||CEA BiTE mAb||Various cancer types||I|
|AZD1775 (+ Lynparza)||PARP inhibitor + Wee1 inhibitor||Various cancer types||I|
|MEDI9197||TLR7/8 agonist||Various cancer types||I|
|durvalumab (+ AZD1775)||PDL1 mAb + Wee1 inhibitor||Various cancer types||I|
|MEDI9447||CD73 mAb||Various cancer types||I|
|durvalumab (+ MEDI9447)||PD-L1 mAb + CD73 mAb||Various cancer types||I|
|durvalumab (+ MEDI0562)||PD-L1 mAb + humanised OX40 agonist||Various cancer types||I|
|durvalumab (+ tremelimumab)||PD-L1 mAb + CTLA-4 mAb||Various cancer types||I|
|durvalumab (+ selumetinib)||PD-L1 + MEK inhibitor||Various cancer types||I|
|durvalumab (+ monalizumab)||PD-L1 mAb + NKG2a mAb||Various cancer types||I|
|tremelimumab (+ MEDI0562)||CTLA-4 mAb + humanised OX40 agonist||Various cancer types||I|
View additional information on product candidates here »
10/27/2016 04:40 pm
(StreetInsider) Oct 27, 2016 - AstraZeneca declined Thursday, falling over 4% intraday. Chatter suggested weakness was related to a halt in recruitment for its trial evaluating its IO combo in head and neck cancer.
10/10/2016 04:15 pm
(Bloomberg) Oct 9, 2016 - AstraZeneca is racing Roche Holding AG and Bristol-Myers Squibb Co. to be first to the market with a two-drug treatment that helps more newly-diagnosed people.
10/10/2016 04:14 pm
(Reuters) Oct 8, 2016 - The failure of Bristol-Myers Squibb's blockbuster Opdivo immunotherapy in previously untreated lung cancer patients has opened up the market for AstraZeneca, its chief executive believes.
10/4/2016 05:24 pm
(Bloomberg) Oct 3, 2016 - AstraZeneca Plc, the U.K.’s second-largest drugmaker, won the endorsement of the country’s health-cost regulator for use of its Tagrisso medicine in some patients with an aggressive form of lung cancer after agreeing to offer the pill at a reduced price.
9/21/2016 04:50 pm
(The Telegraph [UK]) Sept 21, 2016 - AstraZeneca has suffered a setback after being forced to withdraw an application for a key ovarian cancer drug to be approved, citing “differences of opinion” with the European regulator.
9/21/2016 12:03 pm
(Bloomberg) Sept 21, 2016 - AstraZeneca Plc said it is withdrawing an application for European approval for an ovarian-cancer medicine following disagreement with regulatory authorities.
8/24/2016 04:19 pm
(FoxNews/Reuters) Aug 24, 2016 - Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc in a deal that could be valued at more than $1.5 billion.
8/22/2016 04:32 pm
(Wall Street Journal) Aug 22, 2016 - AstraZeneca PLC said Monday that the Alzheimer’s drug it is codeveloping with Eli Lilly & Co. has received fast-track designation from the U.S. Food and Drug Administration, a status designed to speed up the development of promising new medicines.
8/12/2016 04:17 pm
(Bloomberg) Aug 12, 2016 - AstraZeneca Plc, once deemed a laggard in the hot field of immuno-oncology, has rallied 37 percent since its June low with a stable of experimental cancer drugs suddenly gaining allure in the wake of a rival’s failure and speculation of a takeover.
8/11/2016 04:54 pm
(Reuters) Aug 10, 2016 - AstraZeneca has invested another $140 million in Moderna Therapeutics, the U.S. biotech "unicorn" which already has a cash pile of around $1 billion and is developing drugs based on a molecule known as messenger RNA.
8/9/2016 04:50 pm
(PipelineReview.com) Aug 9, 2016 - AstraZeneca today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC).
8/9/2016 11:54 am
(Bloomberg) Aug 9, 2016 - AstraZeneca Plc’s experimental medicine selumetinib failed to keep a common form of lung cancer at bay in an advanced clinical test, making it the second drugmaker to report a setback in battling tumors of the lung this month.
7/21/2016 04:09 pm
(New York Times) July 20, 2016 - The Food and Drug Administration said Wednesday that it had approved generic versions of the blockbuster cholesterol-lowering pill Crestor, rejecting a last-ditch and controversial effort by AstraZeneca to stop cheaper competition from reaching pharmacy shelves.
7/21/2016 12:04 pm
(The Telegraph [UK]) July 20, 2016 - A breakthrough lung cancer drug developed by UK scientists, which passed final clinical trials this week, might not be available on the NHS because it has been deemed too expensive by the drugs watchdog, it has emerged.
7/13/2016 03:40 pm
(MarketWatch) July 13, 2016 - AstraZeneca PLC has entered an agreement with Sandoz, Inc. and affiliates to resolve a U.S. patent litigation relating to its hormonal therapy drug Faslodex, the British pharmaceutical giant said Wednesday.
7/13/2016 12:07 pm
(Reuters) July 13, 2016 - British drugmaker AstraZeneca Plc said on Wednesday it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG, to resolve Faslodex patent litigation in the U.S.
7/12/2016 03:28 pm
(Pharmafile [UK]) July 12, 2016 - Anglo Swedish drug firm AstraZeneca is considering a $10-billion takeover bid for Medivation, according to reports.
6/16/2016 12:00 pm
(STAT) June 15, 2016 - The Department of Energy says it may have found a fast way to find new tactics for treating cancer: Supercomputers.
6/16/2016 11:03 am
(Exact Sciences) June 15, 2016 - Exact Sciences Corp. today announced that the U.S. Preventive Services Task Force (USPSTF) issued its final 2016 colorectal cancer screening recommendations and clarified the inclusion of Cologuard® (FIT-DNA) on equal standing among the other included screening tests.
6/15/2016 11:05 am
(U.S. News & World Report/HealthDay News) June 14, 2016 - Three widely used erectile dysfunction drugs -- Cialis, Levitra and Viagra -- aren't likely to boost the risk of melanoma skin cancer, a new study reports.
6/15/2016 11:05 am
(Jagwire/Augusta University) June 13, 2016 - Researchers want to turn the tide by protecting the kidneys while improving cisplatin’s efficacy against cancer.
6/6/2016 07:27 pm
(The Telegraph [UK]) June 6, 2016 - A breakthrough oncology drug from AstraZeneca is showing promising long-term results in women with ovarian cancer, one of its leading scientists has revealed at a closely-watched pharmaceuticals conference.
6/5/2016 11:37 pm
(AstraZeneca) June 4, 2016 - Foundation Medicine, Inc. and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development program.
6/5/2016 06:00 pm
(2016 ASCO Annual Meeting) June 5, 2016 – A Canadian-led randomized phase III trial found that adding temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%.
6/5/2016 06:00 pm
(2016 ASCO Annual Meeting) June 5, 2016 – A National Cancer Institute (NCI) funded phase III trial performed by the Children's Oncology Group found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient's own stem cells) to standard therapy improves outcomes for patients.
6/5/2016 05:05 pm
(STAT/In the Lab) June 5, 2016 - Older women being treated for the most common form of breast cancer who took drugs called aromatase inhibitors for 10 years rather than the usual five had a lower risk of their cancer returning, particularly in the opposite breast, physicians reported Sunday at the annual meeting of the American Society of Clinical Oncology.
6/3/2016 01:03 pm
(MedPage Today) June 2, 2016 - Development of a software tool to aid cancer therapy decision making will continue toward a pilot study by the end of the year, following tweaking in response to feedback on a draft proposal.
6/2/2016 11:03 am
(Moffitt Cancer Center) June 2, 2016 - Small cell lung cancer represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options.
5/27/2016 03:20 pm
(MarketWatch) May 27, 2016 - AstraZeneca PLC said Friday it had positive results from the Phase III hormonal therapy trial comparing the Faslodex drug to Arimidex in the treatment of breast cancer.
5/27/2016 11:51 am
(AstraZeneca) May 27, 2016 - AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer.
5/27/2016 10:03 am
(TheStreet.com) May 27, 2016 - FDA rejects AstraZeneca's potassium-lowering drug, which means Relypsa's competing drug, already approved, has the commercial market all to itself.
5/20/2016 11:04 am
(Benzinga) May 19, 2016 - BLINCYTO® (blinatumomab) TOWER study demonstrates improved overall survival versus standard of care in patients with B-Cell precursor acute Lymphoblastic Leukemia; TOWER Study to be presented at Presidential Symposium as a Best Abstract; sub-group analyses from pivotal head-to-head phase 3 studies provide further insight Into Kyprolis® (carfilzomib) as treatment option for patients With Multiple Myeloma; Aranesp® (darbepoetin alfa) phase 3 ARCADE data demonstrates significant reduction in red blood cell transfusions in anemic patients With Myelodysplastic Syndrome.
5/20/2016 11:04 am
(Yahoo! Finance) May 19, 2016 - Preliminary data from CONTEMPO, a phase 1b/2 combination study evaluating duvelisib in treatment-naïve patients with follicular lymphoma, to be presented at EHA.
5/19/2016 05:29 pm
(AstraZeneca) May 19, 2016 - AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive investigational oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2016.
5/18/2016 05:06 pm
(Reuters) May 18, 2016 - There have also been setbacks, including the loss of a fast-to-market opportunity for AstraZeneca's big immuno-oncology hope durvalumab.
5/18/2016 04:39 pm
(Bloomberg) May 18, 2016 - AstraZeneca Plc’s ovarian cancer medicine Lynparza didn’t improve survival in patients with advanced gastric cancer, though the U.K. drugmaker said it remains confident in the drug’s ability to battle a range of tumor types.
5/18/2016 11:23 am
(AstraZeneca) May 18, 2016 - AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein.
5/10/2016 11:04 am
(Nature.com) May 9, 2016 - Scientists attack Siddhartha Mukherjee’s feature exploring gene regulation.
4/29/2016 11:01 am
(EMA) Apr 29, 2016 - The European Medicines Agency (EMA) has recommended extending the authorised indication of Gazyvaro (obinutuzumab) to treat patients with follicular lymphoma. The medicine is to be used in combination with bendamustine in patients who were previously treated with chemotherapy.
4/27/2016 12:01 pm
(PRWEB) Apr 26, 2016 - The European Patent Office (EPO) today announced that M.I.T. Professor Robert Langer has been named as one of three finalists for the European Inventor Award 2016 in the category “Non-European countries.”
4/20/2016 12:03 pm
(New York Times/Kaiser Health News) Apr 20, 2016 - High rates of infections and other complications are prompting lower payments from Medicare, as well as protests from some elite hospitals.
4/20/2016 12:02 pm
(AJMC) Apr 19, 2016 - With patients increasingly demanding more of anyone involved in their healthcare, technology is playing an important role, explained panelists at a session of Specialty Pharmacy Connect, a pre-meeting program held ahead of the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
4/19/2016 02:01 pm
(NPR/Shots blog) Apr 18, 2016 - The number of genetic counselors, the people who help both doctors and patients make sense of these tests, hasn't expanded enough to keep up with that demand.
4/19/2016 01:05 pm
(UPMC) Apr 19, 2016 - Taken multiple times a day, watercress extract significantly inhibits carcinogen activity in smokers, a Pitt clinical trial showed.
4/19/2016 01:04 pm
(The Times of India/IANS) Apr 19, 2016 - An Indian-American scientist has engineered T-cells - a type of immune cells - to break the pancreatic cancer's physical and immunological walls using immunotherapy.
4/5/2016 11:02 am
(TheStreet) Apr 4, 2016 - Gilead Sciences is paying $400 million upfront to acquire an early-stage pipeline of liver disease drugs from privately held Nimbus Therapeutics, the companies announced Monday.
4/5/2016 11:01 am
(URMC) Apr 4, 2016 - The results of an early-stage (phase 1b) clinical trial for pancreatic cancer show that an experimental therapy can control tumors well enough to make some patients eligible for surgery, according to data published in The Lancet Oncology by a Wilmot Cancer Institute investigator.
3/31/2016 11:03 am
(Highmark) Mar 30, 2016 - Highmark Inc, an independent licensee of the Blue Cross and Blue Shield Association, today announced its new Highmark Cancer Collaborative.
3/31/2016 11:03 am
(Pacific Business News) Mar 30, 2016 - Researchers at the University of Hawaii Cancer Center and John A. Burns School of Medicine in Honolulu have been awarded $3 million by the Department of Defense for mesothelioma-related research projects.
3/29/2016 11:02 am
(Penn Medicine) Mar 29, 2016 - Insurers increasingly require patients to share the high costs of specialty drugs. Two new studies led by researchers at the Perelman School of Medicine at the University of Pennsylvania have found evidence that such cost-sharing arrangements are associated with significant reductions in access to these medications.